Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1448 | Exercise training group Wiki | 0.41 |
| drug3905 | Tap water Wiki | 0.41 |
| drug1128 | DAS181 COVID-19 Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3114 | Prophylactic/Intermediate Dose Enoxaparin Wiki | 0.41 |
| drug1129 | DAS181 OL Wiki | 0.41 |
| drug4617 | non-interventional Wiki | 0.41 |
| drug1422 | Essential oils Wiki | 0.41 |
| drug1052 | Convalescent Plasma Transfusion Wiki | 0.29 |
| drug3040 | Povidone-Iodine Wiki | 0.20 |
| drug1959 | Interferon Beta-1A Wiki | 0.20 |
| drug1396 | Enoxaparin Wiki | 0.11 |
| drug2029 | Ivermectin Wiki | 0.09 |
| drug2916 | Placebo Wiki | 0.05 |
| drug1775 | Hydroxychloroquine Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000073296 | Noncommunicable Diseases NIH | 0.58 |
| D018184 | Paramyxoviridae Infections NIH | 0.24 |
| D002908 | Chronic Disease NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007154 | Immune System Diseases NIH | 0.17 |
| D003327 | Coronary Disease NIH | 0.15 |
| D051436 | Renal Insufficiency, Chronic NIH | 0.14 |
| D050177 | Overweight NIH | 0.14 |
| D007674 | Kidney Diseases NIH | 0.11 |
| D006331 | Heart Diseases NIH | 0.11 |
| D003141 | Communicable Diseases NIH | 0.09 |
| D007251 | Influenza, Human NIH | 0.09 |
| D002318 | Cardiovascular Diseases NIH | 0.07 |
| D007249 | Inflammation NIH | 0.07 |
| D012141 | Respiratory Tract Infections NIH | 0.07 |
| D007239 | Infection NIH | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.14 |
| HP:0000077 | Abnormality of the kidney HPO | 0.11 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.07 |
Navigate: Correlations HPO
There are 6 clinical trials
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Description: Removal of all oxygen support (with stable SpO2)
Measure: Percent of subjects who Return to Room Air (RTRA) (main study) Time: by Day 28This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
Description: Percent of subjects who have returned to room air
Measure: Percent of subjects who have returned to room air Time: 7 daysDescription: Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1
Measure: Percent change of subjects return to baseline oxygen requirement Time: 7 daysThe objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Description: Percent of subjects with improved clinical status
Measure: Improved clinical status Time: Day 14Description: Percent of subjects return to room air
Measure: Return to room air Time: Day 14Description: time to SARS-CoV-2 RNA in the respiratory specimens being undetectable
Measure: SARS-CoV-2 RNA Time: 28 daysDescription: Percent of patients discharge from hospital
Measure: Discharge Time: Days 14, 21, 28Description: All-cause mortality rate
Measure: Death Time: Day 14, 21, 28It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.
Description: Percent of subjects who reach level 1 of COVID-19 Clinical Classification (discharged or return to normal activity)
Measure: Percent of subjects who have recovered Time: Day 5, 10, 14, 21, 28Description: time to Improved COVID-19 Clinical Classification 1 to 6 (where higher score means worse outcome)
Measure: Improved COVID-19 Clinical Classification Time: Day 28Description: Percent of subjects RTRA
Measure: Return To Room Air (RTRA) Time: Day 10, 21, 28Description: Time to
Measure: SARS-CoV-2 RNA undetectable Time: Day 28Description: Time to
Measure: Clinical Deterioration Time: Day 28Description: Percent of subjects discharge
Measure: Percent of subjects discharged Time: Day 14, 21, 28Description: Time to
Measure: Death (all cause) Time: Day 28It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.
Description: Percent of subjects who reach level 1 of COVID-19 Clinical Classification (discharged or return to normal activity)
Measure: Percent of subjects who have recovered Time: Day 5, 10, 14, 21, 28Description: time to Improved COVID-19 Clinical Classification 1 to 6 (where higher score means worse outcome)
Measure: Improved COVID-19 Clinical Classification Time: Day 28Description: Percent of subjects RTRA
Measure: Return To Room Air (RTRA) Time: Day 10, 21, 28Description: Time to
Measure: SARS-CoV-2 RNA undetectable Time: Day 28Description: Time to
Measure: Clinical Deterioration Time: Day 28Description: Percent of subjects discharge
Measure: Percent of subjects discharged Time: Day 14, 21, 28Description: Time to
Measure: Death (all cause) Time: Day 28On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.
Measure: Geographical distribution of the interventional studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.
Measure: Geographical distribution of the Observational studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.
Measure: Monthly Research study completion rate as per geographic distribution of the Research. Time: 15th of August 2020Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports